Investigational New Drug (IND)

Scientist in laboratory
#Clinical trial #Dicot Pharma #Investigational New Drug (IND)

FDA approves trial of erectile dysfunction treatment 

The US Food and Drug Administration (FDA) has granted Dicot Pharma approval to roll out the Phase IIb study of a treatment for erectile dysfunction.  The approval follows an Investigational New Drug (IND) Application submitted to the FDA, with the trial evaluating LIB-01 now set to commence in the US.  Dicot Pharma says LIB-01… Read More

#News #Regulatory

#FDA #Investigational New Drug (IND) #Melanoma #Scancell Holdings

FDA clears IND application for melanoma treatment 

The US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a registration Phase III trial of iSCIB1+ Immunobody in advanced melanoma.  The application, submitted by biotechnology company Scancell Holdings, has been cleared with progression free survival as the agreed surrogate endpoint.  Scancell has completed the 140-patient SCOPE Phase II, open-label, multi-centre… Read More

#News #Regulatory

#FDA #Investigational New Drug (IND) #Leukaemia #Lymphoma

FDA grants IND clearance to novel BTK degrader 

A novel treatment for relapsed/refractory B-cell malignancies has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA).  APG-3288, developed by biopharmaceutical company Ascentage Pharma, is a novel next-generation BTK-targeted protein degrader. The candidate is designed to induce rapid, potent, highly selective, and sustained degradation of both wild-type BTK… Read More

#News #Regulatory

Approval stamp
#Alopecia #Alys Pharmaceuticals #Clinical trials #FDA #Health Canada #Investigational New Drug (IND)

Clearance for first genetic medicine programme in dermatology

The US Food and Drug Administration (FDA) and Health Canada have cleared Alys Pharmaceuticals’ Investigational New Drug (IND) / Clinical Trial Application (CTA) for the study of ALY-101 in patients suffering from Alopecia Areata (AA). The Phase IIa trial will evaluate the safety and efficacy of ALY-101, an intradermal injectable… Read More

#News #Regulatory